Orphan Drugs | Access and Reimbursement | US | 2016
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both utilization and costs of orphan drugs. The study further explores U.S. payers’ perspectives on market access considerations for several rare diseases including cystic fibrosis, Duchenne muscular dystrophy, hemophilia A, and idiopathic pulmonary fibrosis.
Related Market Assessment Reports
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
